A Phase 3 interventional study of Solumedrol in Active Rheumatoid Arthritis, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by Sohag University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Arthritis, Rheumatoid by Sohag University — 10 open to participants now, 11 under way, 1 of them phase 3. Arthritis, Rheumatoid · Sohag University.
Among the 20 studies in Arthritis, Rheumatoid by Sohag University, this one is one of 3 that started in 2024, is the only one in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 9th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →10 of the 20 studies in Arthritis, Rheumatoid by Sohag University are open now, in 1 country. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18+ · Healthy volunteers
Sohag University · Sites in Egypt
Ages 18–65
Sohag University
Ages 18+ · Healthy volunteers
Sohag University
Ages 18+
Sohag University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 268 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 60 across the 8 interventional studies, 126 across the 12 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
6 of the studies in Arthritis, Rheumatoid by Sohag University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07814989Sohag UniversityWrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis | 2027-01-01 |
| NCT07801261Sohag UniversityEvaluation of Functional Disability in Rheumatoid Arthritis Patients | 2027-01-20 |
| NCT07878611Sohag UniversityMusclockeletal Ultra-sound Assessment of Pulley Inflammation in Rheumatoid Arthrits Pateints | 2027-03 |
| NCT07393217Sohag UniversityCorrelation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis) | 2027-03-01 |
| NCT07381296Sohag UniversityPrognostic Factors and Predictors of Disease Flare in Patients With Rheumatoid Arthritis | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies in Arthritis, Rheumatoid by Sohag University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Remission or low disease activity in active rheumatoid arthritis
Assessment of rheumatoid arthritis activity by Disease activity score DAS28, DAS28 Erythrocyte sedimentation rate (ESR), American college of rheumatology (ACR) 20, ACR 50, ACR 70 will be done at baseline and every month for 3 consecutive months for both groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
125 mg of methylprednisolone IV pulse will be administered for two consecutive days followed by oral steroid for 2 weeks with gradual withdrawal.
Drug: Solumedrol
patients will not receive any additional treatment
Drug: Solumedrol
125 mg methylprednisolone intravenous pulse on 2 consecutive days
remission or low disease activity
Outcome measurements for both groups will be done at baseline and every month for 3 months. DAS28, DAS28 ESR ACR20 ACR50 ACR70
Time frame: 4 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Sep 2024, 4 months after the start.
Of 148 phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 40. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone Hemisuccinate